vs

Side-by-side financial comparison of MERCANTILE BANK CORP (MBWM) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

MERCANTILE BANK CORP is the larger business by last-quarter revenue ($67.6M vs $35.5M, roughly 1.9× RECURSION PHARMACEUTICALS, INC.). MERCANTILE BANK CORP runs the higher net margin — 33.6% vs -304.2%, a 337.8% gap on every dollar of revenue. Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 9.1%).

Tamilnad Mercantile Bank Limited (TMB) is an Indian bank headquartered at Thoothukudi, Tamil Nadu. TMB was founded in 1921 as the Nadar Bank, but changed its name to Tamilnad Mercantile Bank in November 1962 to widen its appeal beyond the Nadar community. The bank currently has 600 full branches throughout India, 12 regional offices and two link offices, two central processing centres, one service branch, four currency chests, 48 eLobby centres, 262 cash recycler machines and 1151 automated ...

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

MBWM vs RXRX — Head-to-Head

Bigger by revenue
MBWM
MBWM
1.9× larger
MBWM
$67.6M
$35.5M
RXRX
Higher net margin
MBWM
MBWM
337.8% more per $
MBWM
33.6%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
9.1%
MBWM

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
MBWM
MBWM
RXRX
RXRX
Revenue
$67.6M
$35.5M
Net Profit
$22.7M
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
33.6%
-304.2%
Revenue YoY
681.7%
Net Profit YoY
16.1%
39.6%
EPS (diluted)
$1.32
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MBWM
MBWM
RXRX
RXRX
Q1 26
$67.6M
Q4 25
$62.1M
$35.5M
Q3 25
$62.4M
$5.2M
Q2 25
$60.9M
$19.2M
Q1 25
$57.3M
$14.7M
Q4 24
$58.5M
$4.5M
Q3 24
$58.0M
$26.1M
Q2 24
$56.8M
$14.4M
Net Profit
MBWM
MBWM
RXRX
RXRX
Q1 26
$22.7M
Q4 25
$22.8M
$-108.1M
Q3 25
$23.8M
$-162.3M
Q2 25
$22.6M
$-171.9M
Q1 25
$19.5M
$-202.5M
Q4 24
$19.6M
$-178.9M
Q3 24
$19.6M
$-95.8M
Q2 24
$18.8M
$-97.5M
Gross Margin
MBWM
MBWM
RXRX
RXRX
Q1 26
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Operating Margin
MBWM
MBWM
RXRX
RXRX
Q1 26
Q4 25
42.0%
-304.8%
Q3 25
44.0%
-3327.6%
Q2 25
42.6%
-916.8%
Q1 25
42.0%
-1297.9%
Q4 24
39.7%
-4042.4%
Q3 24
42.4%
-377.1%
Q2 24
41.4%
-697.4%
Net Margin
MBWM
MBWM
RXRX
RXRX
Q1 26
33.6%
Q4 25
36.8%
-304.2%
Q3 25
38.1%
-3135.3%
Q2 25
37.1%
-894.2%
Q1 25
34.1%
-1373.3%
Q4 24
33.5%
-3935.5%
Q3 24
33.8%
-367.5%
Q2 24
33.1%
-676.6%
EPS (diluted)
MBWM
MBWM
RXRX
RXRX
Q1 26
$1.32
Q4 25
$1.41
$-0.17
Q3 25
$1.46
$-0.36
Q2 25
$1.39
$-0.41
Q1 25
$1.21
$-0.50
Q4 24
$1.20
$-0.56
Q3 24
$1.22
$-0.34
Q2 24
$1.17
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MBWM
MBWM
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$1.5M
$9.6M
Stockholders' EquityBook value
$736.9M
$1.1B
Total Assets
$6.9B
$1.5B
Debt / EquityLower = less leverage
0.00×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MBWM
MBWM
RXRX
RXRX
Q1 26
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Total Debt
MBWM
MBWM
RXRX
RXRX
Q1 26
$1.5M
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Stockholders' Equity
MBWM
MBWM
RXRX
RXRX
Q1 26
$736.9M
Q4 25
$724.9M
$1.1B
Q3 25
$657.6M
$1.0B
Q2 25
$631.5M
$919.1M
Q1 25
$608.3M
$933.9M
Q4 24
$584.5M
$1.0B
Q3 24
$583.3M
$524.6M
Q2 24
$551.2M
$584.4M
Total Assets
MBWM
MBWM
RXRX
RXRX
Q1 26
$6.9B
Q4 25
$6.8B
$1.5B
Q3 25
$6.3B
$1.4B
Q2 25
$6.2B
$1.3B
Q1 25
$6.1B
$1.3B
Q4 24
$6.1B
$1.4B
Q3 24
$5.9B
$726.5M
Q2 24
$5.6B
$775.9M
Debt / Equity
MBWM
MBWM
RXRX
RXRX
Q1 26
0.00×
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MBWM
MBWM
RXRX
RXRX
Operating Cash FlowLast quarter
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MBWM
MBWM
RXRX
RXRX
Q1 26
Q4 25
$18.0M
$-46.1M
Q3 25
$23.1M
$-117.4M
Q2 25
$-7.8M
$-76.4M
Q1 25
$-3.0M
$-132.0M
Q4 24
$101.1M
$-115.4M
Q3 24
$-8.1M
$-59.2M
Q2 24
$9.1M
$-82.2M
Free Cash Flow
MBWM
MBWM
RXRX
RXRX
Q1 26
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
FCF Margin
MBWM
MBWM
RXRX
RXRX
Q1 26
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Capex Intensity
MBWM
MBWM
RXRX
RXRX
Q1 26
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Cash Conversion
MBWM
MBWM
RXRX
RXRX
Q1 26
Q4 25
0.79×
Q3 25
0.97×
Q2 25
-0.35×
Q1 25
-0.15×
Q4 24
5.15×
Q3 24
-0.41×
Q2 24
0.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MBWM
MBWM

Net Interest Income$55.9M83%
Noninterest Income$11.7M17%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons